Safety profile in moderate to severe plaque psoriasis across
2 clinical trials1,2
Adverse events in the 16-week, placebo-controlled period of the VOYAGE 1 and VOYAGE 2 pooled clinical trials1,2
In the 16-week, placebo-controlled period of the VOYAGE 1 and VOYAGE 2 pooled clinical trials:
- The most common (≥1%) infections were upper respiratory infections, gastroenteritis, tinea infections, and herpes simplex infections; all cases were mild to moderate in severity and did not lead to discontinuation of TREMFYA®
Pooled safety data from VOYAGE 1 and VOYAGE 2 through 5 years (Week 264)2*
*Safety summary includes all patients exposed to TREMFYA®.
Humira is a registered trademark of Abbvie Biotechnology Ltd. Corporation.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.